MIR6750: MIR6750 is a human splicing-derived miRNA, also known as a "mirtron" [PMC8569761]. In a study analyzing serum and urine samples, the expression levels of MIR6750 were found to be non-significant between the patient and control group [PMC8569761]. However, MIR6750 was upregulated in both urine and serum samples of patients with prostate cancer compared to healthy controls [PMC8569761]. The expression levels of MIR6750 were higher in serum samples compared to urine specimens in patients with prostate cancer [PMC8569761]. The accuracy of miRNA quantification was confirmed by reexamining MIR6750 using qRT-PCR in a subset of samples [PMC8569761]. In addition to prostate cancer, downregulation of MIR6750 has been observed in nonsmall cell lung cancer by silencing the insulin-like growth factor 1 receptor (IGF-1R) gene [PMC8569761]. The study also identified other miRNAs that were detected in both urine and serum samples from both patients and healthy controls, including MIR320A [PMC8569761]. Furthermore, an miRNA expression signature analysis identified several top-ranked miRNAs including MIR6750 that may be relevant in prostate cancer [PMC9284388]. Overall, while the significance of MIR6750 in prostate cancer is still being explored, it shows potential as a biomarker for this disease.